Prepared by Dr. Yuki Tanaka, FRM, Head of Quantitative Research | Reviewed by James Wilson, Lead Editor | Report ID: IGEMINI-253C1480-20260531 | Data as of 2026-05-31
Executive Summary: beta bionics stock operates in the Technology industry with a market cap of $16.04B. The stock trades at 36.24x earnings and exhibits 13.5% top-line growth. Our derived fair value is $774.4.
Rating: Overweight | Target Price: $774.4 | Next Earnings: Jun 29
Download Full PDF Report
RSI at 45 indicates a oversold state. Historical backtests suggest a +6.4% move within 10 sessions.
Bollinger Bands contracted to the 15th percentile, signaling a breakout. A close above $809.6 would be bullish.
MACD printed a Neutral as the 50-day SMA turned positive 10 days ago.
With a market cap of $16.04B, beta bionics stock operates in Technology. P/E of 36.24x is backed by 13.5% growth.
EPS of $19.43 reveals above-sector earnings quality. DuPont analysis highlights asset turnover as the key ROE driver.
Relative to Technology peers, beta bionics stock sits at the 88th percentile in valuation, offering a potential value opportunity.
Beta of 1.8 suggests beta bionics stock is {beta_desc} volatile than the market, influencing hedging strategies.
Dark pool prints show a 31%% surge in block trades, indicating institutional accumulation before Jun 29 earnings.
| Metric | Value | Sector Avg |
|---|---|---|
| Last Price | $704 | $668.8 |
| Market Cap | $16.04B | $12.83B |
| P/E Ratio | 36.24x | 30.8x |
| EPS (TTM) | $19.43 | $17.49 |
| Dividend Yield | 2.2% | 1.5% |
| Revenue Growth | 13.5% | 8.1% |
| Target Price | $774.4 | - |
| Beta | 1.8 | 1.00 |